|CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.|
|PMID: 22685579 Owner: NLM Status: MEDLINE|
|BACKGROUND: TNFα inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFα inhibitors in patients with rheumatoid arthritis (RA).
METHODOLOGY AND PRINCIPAL FINDINGS: In the DANBIO Registry we identified 237 TNFα inhibitor naïve patients with RA (81% women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n=160), adalimumab (n=56) or etanercept (n=21) between 1999 and 2008 according to national treatment guidelines. Clinical response was assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA and treatment response using the GeneVa® (Compugen) in silico database of 350,000 genetic variations in the human genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR good response versus moderate/no response using Fisher's exact test. At baseline the median DAS28 was 5.1. At week 26, 68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders, respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response (OR=4.43, 95% CI: 1.99-10.09, p=7.211×10(-5)) and with EULAR good response vs. moderate/no response (OR=4.54, 95% CI: 2.29-8.99, p=3.336×10(-6)). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR good response vs. no response (OR=4.01, 95% CI: 1.92-8.49, p=5.067×10(-5)).
CONCLUSION: Genetic variations within CD6 and STXBP6 may influence response to TNFα inhibitors in patients with RA.
|Sophine B Krintel; Laurent Essioux; Assaf Wool; Julia S Johansen; Ehud Schreiber; Tomer Zekharya; Pinchas Akiva; Mikkel Ostergaard; Merete L Hetland|
Related Documents :
|11515619 - The outcome in myasthenia gravis patients--an eight-year follow-up after finishing immu...
3329519 - Angioimmunoblastic lymphadenopathy with dysproteinemia in thailand.
1973409 - Different hla dr-dq associations in subgroups of idiopathic myasthenia gravis.
3597859 - Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125 patients.
12451369 - Primary follicular mucinosis: long-term follow-up of patients younger than 40 years wit...
18791469 - Differential orbicularis oculi involvement in neuromuscular junction dysfunction.
21178289 - Comparison of qt/rr relation based on a 15-s averaged ecg and a single beat ecg during ...
4030709 - The clinical effectiveness and safety of chronic plasmapheresis in patients with primar...
20859229 - Antisynthetase syndrome presenting as rheumatoid-like polyarthritis.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-06-07|
|Title: PloS one Volume: 7 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2012|
|Created Date: 2012-06-11 Completed Date: 2012-12-07 Revised Date: 2013-07-12|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e38539 Citation Subset: IM|
|DANBIO Registry and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, CD / genetics*
Antigens, Differentiation, T-Lymphocyte / genetics*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*, genetics*
Carrier Proteins / genetics*
DNA Mutational Analysis
Immunoglobulin G / therapeutic use
Polymerase Chain Reaction
Receptors, Tumor Necrosis Factor / therapeutic use
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
|0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antigens, CD; 0/Antigens, Differentiation, T-Lymphocyte; 0/Antirheumatic Agents; 0/CD6 antigen; 0/Carrier Proteins; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/STXBP6 protein, human; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsai...
Next Document: BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells ...